Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 519 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+ - NCT05112549RecruitingPhase 1
PD-1 antibody placed into brain fluid for metastatic cancer
This early-phase study tests a PD-1 antibody delivered directly into the brain fluid (intrathecal space) to treat metastatic solid tumors that have spread to the lining around the brain/spinal cord (leptomeningeal disease). It aims to see whether this approach can better control cancer in that area and whether it’s safe.
BonnAges 18 years+ - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT05904301Recruiting
Registry for autoimmune and autoinflammatory disease patients
This study builds a nationwide list (registry) of people with certain autoimmune or inflammation-related illnesses. It helps researchers understand these diseases better over time, which can guide future care.
YerevanAges Any age - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06584045Recruiting
Testing a bile-based treatment for adult encephalitis
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
Wuhan, HubeiAges 18 years+ - NCT07216014RecruitingPhase 4
IL-23 antibody for inflammatory bowel disease
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
Guangzhou, GuangdongAges 18–65 - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT07208149RecruitingPhase 1/Phase 2
Study of MR001 for advanced triple-negative breast cancer
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
BeijingAges 18–75 - NCT06857227RecruitingPhase 1
Study of GNC-038 for active rheumatoid arthritis
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07205874Recruiting
Finding PBC early in people with positive AMA
This study looks for early signs of Primary Biliary Cholangitis in people who have a positive AMA blood test but normal liver enzyme levels. It aims to find the disease before it causes symptoms.
MadridAges 18–80 - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT07202494Recruiting
Brain aging and resilience MRI study
This study uses powerful MRI scans to understand how the brain ages and why some people stay healthy while others develop neurological diseases like multiple sclerosis or Alzheimer's. It compares healthy volunteers to people with certain conditions, and all participants get a detailed brain MRI.
MarseilleAges 18–90 - NCT07191249RecruitingPhase 2
Mosunetuzumab for low-tumor-burden follicular lymphoma
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
HaifaAges 18 years+ - NCT07183865RecruitingPhase 2
Radiation, chemo, and immunotherapy for recurrent rectal cancer
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT07178171RecruitingPhase 1
QL1706 + short chemo for early triple-negative breast cancer
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–70 - NCT07174908RecruitingPhase 3
New drug combo vs standard therapy for KRAS G12C lung cancer
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Beijing, Beijing MunicipalityAges 18–80 - NCT06613490RecruitingEarly Phase 1
CAR NK cells for antibody syndrome and rheumatoid arthritis
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
Nanjing, JiangsuAges 18–70
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 519 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.